Atopic Dermatitis

Christopher Bunick, MD, PhD, introduces an integrated analysis of phase three studies analyzing the long-term safety of upadacitinib as treatment for atopic dermatitis (AD). He also highlights a burgeoning standard to assess the safety of treatment.

Ruth Ann Vleugels, MD, MPD, MBA, and Christopher Bunick, MD, PhD, provide their clinical experience with Janus Kinase (JAK) inhibitors and the importance of patient compliance with these agents.

Researchers found that treatment for atopic dermatitis could contribute to a higher mutation rate.

Grant applications are open from now until August 24, 2023, with an anticipated project start/end date of January 2024 through July 2025.

Diego Ruiz Dasilva, MD, FAAD, reviews the difference between clinical presentation of atopic dermatitis in adults vs children, as well as the pathophysiology of the disease.

Trinity Flint, a patient with atopic dermatitis, talks about the initial symptoms she had as a child that led her to see a doctor for diagnosis.

Compared to patients who identified as heterosexual, patients in the LGBTQ+ community have a higher prevalence of atopic dermatitis, asthma, and allergic rhinitis.

Experts discuss a recent network meta-analysis comparing current monotherapies for atopic dermatitis (AD) and how this may change standards of care.

Christopher Bunick, MD, PhD, and Ruth Ann Vleugels, MD, MPD, MBA, discuss the method of action for Janus Kinase (JAK) inhibitors and the pathology of atopic dermatitis (AD).

Researchers conducted a systematic review and meta-analysis of probiotic treatment efficacy in children with atopic dermatitis.

Clinicians James Q. Del Rosso, DO; Raj Chovatiya, MD, PhD; and Lisa Swanson, MD, PhD, review the study, “Rapid Pruritus Reduction With Ruxolitinib Cream in Patients With Atopic Dermatitis."

Children of mothers who took more than 5 courses of antibiotics during pregnancy were at the highest risk.

Adam Friedman, MD, FAAD, and Andrew Alexis, MD, MPH, discuss disparities in atopic dermatitis and the ways these can be addressed with teledermatology.

In a Dermatology Times DermView custom video series, Shawn Kwatra, MD, and Peter Lio, MD, discuss the topical treatment landscape of atopic dermatitis.

Pediatricians are often the first to diagnose and manage pediatric atopic dermatitis, and Larry Eichenfield, MD, led a team to develop a tool to help them.

Peter Lio, MD also explained why he considers it a bad day when he does not learn something new about this disease.

AB-101a is a new topical treatment being investigated for mild, moderate, and severe atopic dermatitis and its immune system component.

The TRuE-AD3 study met its primary endpoint of IGA-TS improvement from baseline at week 8.

Alphyn Biologics announced positive results from their Phase 2a trial of AB-101a will lead to a multinational Phase 2b trial soon.

Dupilumab self-injection has been available to patients in Japan since May 2019.

Examining the genes and signaling pathways of development of atopic dermatitis and tooth agenesis reveals possible link between the two diseases.

Findings indicate no rebound effect when participants discontinue dupilumab.

Pediatric patients with moderate to severe eczema demonstrated an increased risk of experiencing the food allergy.

Experts discuss the history and evolving landscape of topical steroids as therapy for atopic dermatitis (AD).

Peter Lio, MD, FAAD, and Shawn Kwatra, MD, discuss janus kinase (JAK) inhibitors and their recent use in the treatment of atopic dermatitis (AD).

The ongoing Canadian wildfires are causing poor air quality in the US, which will likely result in more patients seeking help for skin conditions.

Sanofi’s investigational anti-OX40-ligand monoclonal antibody showed statistically significant improvement in signs and symptoms of AD in adults.

Experts discuss the symptoms of atopic dermatitis (AD) and how disease severity may impact symptoms.

Shawn Kwatra, MD, and Peter Lio, MD, FAAD, discuss the burden of atopic dermatitis (AD) and how it may affect pediatric or adult patients.

A poster presented at the SDPA Annual Summer Dermatology Conference revealed the abrocitinib did not have a significant impact on adolescent immune responses to Tdap vaccination.